A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment

We recently demonstrated that obinutuzumab (GA101), a novel glycoengineered type II CD20 Ab compared to rituximab (RTX) mediates significantly enhanced antibody-dependent cell cytotoxicity (ADCC) in vitro and increased overall survival in a Burkitt lymphoma (BL) xenograft non-obese diabetic severe c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Awasthi, Aradhana, Rolland, Delphine C.M., Ayello, Janet, van de Ven, Carmella, Basrur, Venkatesha, Conlon, Kevin, Fermin, Damian, Barth, Matthew J, Klein, Christian, Elenitoba-Johnson, Kojo S.J., Lim, Megan S., Cairo, Mitchell S.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5768372/
https://ncbi.nlm.nih.gov/pubmed/29371955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23040
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados